Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety

Inclusion Criteria: * Signed informed consent * Male or female, age ≥ 18 years and ≤ 80 years at the time of signing informed consent. * Report clinically significant symptoms of anxiety, defined as a score of 10 or greater on the Generalized Anxiety Disorder Scale, 7th edition (GAD-7) * Ability and willingness to complete all study visits and procedures * Agreement to engage with using the device on a daily basis * Agreement to engage with trial mentors * Agreement not to use prescription, or over the counter, anxiety medications for the duration of the trial * Access to Wi-Fi * Access to Apple smart phone (If not an Apple iPod will be supplied) Exclusion Criteria: * History of skin breakdown, eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind the ears. * Previous diagnosis of HIV infection or AIDS (HIV is known to cause a vestibular neuropathy which would prevent VeNS from working) * Use of beta-blockers within 1 month of starting the study * Use of antidepressants or unstable dose within 3 months of starting study * Medication for anxiety (unless regime stable for last 3 months). * A history of stroke or severe head injury (as defined by a head injury that required a craniotomy or endotracheal intubation). (In case this damaged the neurological pathways involved in vestibular stimulation). * Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.). * Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice) * History of epilepsy * History of active migraines with aura * History of head injury requiring intensive care or neurosurgery * History of cognitive impairment * History of of bipolar, psychotic or substance use disorders * Regular use (more than twice a month) of antihistamine medication within the last 6 months. * History or presence of malignancy within the last year (except basal and squamous cell skin cancer and in-situ carcinomas) * A diagnosis of myelofibrosis or a myelodysplastic syndrome. * Previous use of Modius device * Participation in other clinical trials sponsored by Neurovalens * Participation in any other anxiety studies * Have a member of the same household who is currently participating in this study. * Not fluent in English language * History of vestibular dysfunction or other inner ear disease